Cargando…
A preliminary clinical trial to evaluate (64)Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer
BACKGROUND: The purpose of this study was to evaluate both the biodistribution and safety of (64)Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel (64)Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients with b...
Autores principales: | Lee, Inki, Lim, Ilhan, Byun, Byung Hyun, Kim, Byung Il, Choi, Chang Woon, Woo, Sang-Keun, Kim, Kwang Il, Lee, Kyo Chul, Kang, Joo Hyun, Seong, Min-Ki, Kim, Hyun-Ah, Noh, Woo Chul, Lim, Sang Moo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818354/ https://www.ncbi.nlm.nih.gov/pubmed/33475899 http://dx.doi.org/10.1186/s13550-021-00746-1 |
Ejemplares similares
-
The Prediction of HER2-Targeted Treatment Response Using (64)Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report
por: Lee, Inki, et al.
Publicado: (2022) -
Early prediction of neoadjuvant chemotherapy response for advanced breast cancer using PET/MRI image deep learning
por: Choi, Joon Ho, et al.
Publicado: (2020) -
Comparison of (99m)Tc-methyl diphosphonate bone scintigraphy and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma
por: Lee, Inki, et al.
Publicado: (2018) -
Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023) -
Deep Learning-Based Delayed PET Image Synthesis from Corresponding Early Scanned PET for Dosimetry Uptake Estimation
por: Kim, Kangsan, et al.
Publicado: (2023)